v3.25.3
Collaborations - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jun. 25, 2025
Jul. 07, 2020
May 09, 2019
Jun. 30, 2025
Sep. 30, 2025
Jun. 30, 2025
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Dec. 31, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Cost reimbursement payment received                 $ 900      
Research and development         $ 74,094   $ 60,410   232,737 $ 168,431    
Revenue         2,764   3,741   36,341 39,678    
Revenue Recognized                 75,000      
Milestone Two [Member]                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Revenue recognized recorded in deferred revenue         0       23,600      
Unconstrained Consideration                       $ 55,000
Collaboration Target 1                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Collaboration revenue recognised                 11,500      
Gilead Agreement                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Upfront payment $ 40,000                      
Option exercise payment 45,000                      
Collaboration agreement transaction price                 40,000      
Revenue recognized recorded in deferred revenue                 $ 37,200   $ 0  
Remaining research term of collaboration                 1 year 6 months      
Revenue         2,800       $ 2,800      
Deferred Revenue         37,200       37,200      
Increase in Revenue           $ 40,000            
Gilead Agreement | Maximum                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Development milestone payments 665,000                      
Commercial Milestone Payments $ 665,000                      
Sanofi Agreement                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Upfront payment   $ 150,000                    
Collaboration agreement transaction price   150,000                    
Revenue recognized recorded in deferred revenue                 33,600   13,600  
Unsatisfied performance obligation         0       0   13,600  
Unconstrained Consideration         20,000       20,000      
Sanofi Agreement | Milestone One [Member]                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Collaboration revenue recognised               $ 40,000        
Sanofi Agreement | Milestone Two [Member]                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Collaboration revenue recognised               $ 15,000        
Sanofi Agreement | Collaboration Target 1                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Collaboration agreement transaction price   120,000                    
Revenue recognized recorded in deferred revenue         0       33,600 $ 39,700    
Revenue             $ 3,700          
Sanofi Agreement | Collaboration Target 2                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Collaboration agreement transaction price   30,000                    
Sanofi Agreement | Maximum                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Development milestone payments   1,480,000   $ 975,000                
Commercial Milestone Payments   $ 700,000   $ 975,000                
Vertex Agreement                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Unsatisfied performance obligation         $ 0       $ 0   $ 0  
Initial research term of collaboration     4 years                  
Extended research term of collaboration     1 year                  
Vertex Agreement | Series B-1 Preferred Stock                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Collaboration agreement transaction price     $ 55,900                  
Non refundable upfront payment received     $ 50,000                  
Stock Issued During Period, Shares, New Issues     3,059,695                  
Stock issued price per share     $ 6.54                  
Preferred stock premium     $ 5,900                  
Vertex Agreement | Maximum                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Eligible to receive payments including development, regulatory and commercial milestones     $ 170,000